Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Alastair Smith, Avacta Group CEO gives an Operational Update


Vectura Share Price (VEC)



Share Price Information for Vectura (VEC)


Share Price: 78.20Bid: 78.45Ask: 78.70Change: 0.00 (0.00%)No Movement on Vectura
Spread: 0.25Spread as %: 0.32%Open: 77.10High: 79.60Low: 76.10Yesterday’s Close: 78.20

Vectura Group Plc Ord 0.025P

Vectura is listed in the FTSE All-Share, FTSE Small Cap
Vectura is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
78.20
Share Price SpacerBid
78.45
Share Price SpacerAsk
78.70
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
1,642,150
Share Price SpacerOpen
77.10
Share Price SpacerHigh
79.60
Share Price SpacerLow
76.10
Share Price SpacerClose
78.20
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 665.30m £520.27m 7,500

52 Week High 127.20 52 Week High Date 28-DEC-2017
52 Week Low 68.00 52 Week Low Date 21-MAR-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
578 1,195,407 359,475 -6.206 -12.60 0.00 0.00


London South East Users info for Vectura




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

21-Sep-18
17:09:58
78.50
427
Sell* 
78.45
78.70
335.20
Trade Type:
Ordinary
Delayed publication

21-Sep-18
18:09:29
78.208
18,534
Sell* 
78.45
78.70
14.50k
Trade Type:
Ordinary

21-Sep-18
17:28:52
78.621
4,882
Buy* 
78.45
78.70
3,838
Trade Type:
Ordinary




View more Vectura trades >>

Directors Deals for Vectura (VEC)
Trade DateActionNotifierPriceCurrencyAmountHolding
08-Nov-17Buy
Trade Notifier Information for Vectura Group
Andrew Derodra held the position of CFO at Vectura Group at the time of this trade.
 Andrew Derodra
96.35GBX156415740
06-Oct-17Buy
Trade Notifier Information for Vectura Group
Andrew Derodra held the position of CFO at Vectura Group at the time of this trade.
 Andrew Derodra
105.9GBX142415584
12-Sep-17Buy
Trade Notifier Information for Vectura Group
Bruno Angelici held the position of Non-Executive Chairman at Vectura Group at the time of this trade.
 Bruno Angelici
98.66GBX70,000162903
View more Vectura directors dealings >>


Dandee
Posts: 375
Opinion:No Opinion
Price:77.45
RE: unloved vec
Fri 08:40
Looking strong this morning.
outofideas
Posts: 567
Opinion:No Opinion
Price:73.75
unloved vec
Tue 16:49
what is it going to take to lift this out of the rut?the results were ok but price still stuck at near 4 year lows
Lindon
Posts: 674
Opinion:Hold
Price:74.00
Shorts update
Mon 19:13
Only one shorter left now (0.6%) The other listed as dropping out the day after results reported. There are also some early signs of some buying increasing.
MrBB
Posts: 1,710
Opinion:No Opinion
Price:76.55
RE: Maybe not long to wait!
13 Sep '18
It would be a glorious irony if Generic Ellipta proved to be the catalyst for a major re rating ( apart from the substantial prospective profitability) with view to our current legal dispute with GSK regarding the royalties .I doubt whether HIK would be interested in acquiring us although they must surely be interested in generic Ellipta- assuming that they have worked will with us in respect of generic Advair.
Ever optimistic !
Lindon
Posts: 674
Opinion:Strong Buy
Price:74.05
Maybe not long to wait!
12 Sep '18
MrBB... ha ha! Hopefully the proposed partnership with one of the majors for this could suddenly be announced at any stage from now... (or at least before the kids section us and send for the men in white coats!!) when it does, it’ll put a massive bonfire under GSK... and light the blue touch-paper for VEC!

I believe the market is still fixated on Advair issues to such an extent that it's missing the importance of the impending introduction of generic options for the Ellipta range... which is becoming a very real near term prospect.

Anticipated Major News flow 2018 -2019 Potential generics licensing deal, H2 2018 Open-Inhaled-Close Device

As previously announced, Vectura has received feedback from the FDA that its Open-Inhale-Close device could be considered for use in an AB-rated substitutable generic drug-device combination for the GSK Ellipta® portfolio.

This is a significant opportunity, with consensus analyst projections of global net sales of the Ellipta® products of approximately $3bn in the US by 2022.

Device and formulation development with Vectura’s Open-Inhale-Close dry powder inhaler is continuing, with good progress being made in parallel with ongoing strategic partnering discussions.

“we continue to make good progress in our open-inhale-closed program, which we talked about for the first time at the beginning of this year. This product is a potential multiproduct development for an AB-rated substitutable generic program addressing the currently strongly performing GSK Ellipta portfolio. Device and formulation development is progressing well, and there is continued interest in partnering this valuable Suite of potential assets”.
View more share chat for Vectura (VEC) >>




Vectura Group Plc Ord 0.025P home pageWebsite: Vectura Group Plc Ord 0.025P
Website Description: Vectura



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.